Top Strike Announces 2020 Fourth Quarter Financial Results, 2020 Annual Financial Results, and Provides Corporate Activity and Update | News

CALGARY, AB, Aug. 28, 2020 /PRNewswire/ – Top Strike Resources Corp. d.b.a. “Vencanna Ventures” (the “Corporation”…

CALGARY, AB, Aug. 28, 2020 /PRNewswire/ – Top Strike Resources Corp. d.b.a. “Vencanna Ventures” (the “Corporation” or “Vencanna“) (CSE: VENI) (OTCQB: TPPRF) is pleased to provide a summary of its financial results as of April 30, 2020. Selected financial information is outlined below and should be read in conjunction with the Corporation’s financial statements and management’s discussion and analysis for the three and twelve months ended April 30, 2020, which are available on SEDAR at www.sedar.com.

Financial Highlights

The following table summarizes key financial highlights associated with the Corporation’s financial performance for the last eight quarters.

($)

Apr 30,
2020

Jan 31,
2020

Oct 31,
2019

Jul 31,
2019

Apr 30,
2019

Jan 31,
2019

Oct 31,
2018

July 31,
2018

Revenue

950,424

307,630

281,650

113,548

222,857

900

95

123

Gain (Loss) for
the period

712,761

59,196

(60,828)

(205,824)

(1,390,478)

(232,744)

(286,799)

(3,285)

Gain (Loss) per
share – basic

0.00

0.00

(0.00)

(0.00)

(0.02)

(0.00)

(0.00)

(0.00)

Total assets

9,293,961

8,671,208

8,438,837

8,468,446

8,603,826

8,633,369

9,231,900

74,211

Total liabilities

76,132

66,268

37,109

58,138

58,370

14,829

449,524

13,088

As of the date hereof, a major portion of the Corporation’s business was derived from material ancillary involvement in US cannabis-related activities. As at April 30, 2020, 59% of the Corporation’s assets and 100% of other income was directly related to US cannabis activities.

Corporate Activity and Update

On September 10, 2019, the Corporation was approved for and commenced a Normal Course issuer bid (the “NCIB“). During the period the Corporation purchased under its NCIB 3,258,000 common shares of the Corporation (“Common Shares“) at an average price of $0.015. To date the Corporation has purchased a total of 6,197,000 Common Shares.

On February 21, 2020, the Corporation announced a subsequent investment in Galenas, LLC (“Galenas Ohio“). The Corporation purchased a convertible promissory note (“GOH Note“) with a face value and cost of US$3.3 million. As of this date, total outstanding including accrued interest on the GOH Note is approximately US$3.8 million. The GOH Note was purchased from Medical Investor Holdings, LLC (d.b.a. Vertical Companies) (“Vertical“). The GOH Note is convertible upon the holder’s option and subject to regulatory approvals, into a 35% non-dilutive equity interest in Galenas Ohio. On July 22, 2019, the Corporation loaned Vertical $4 million for inventory and general working capital purposes (the “Vertical Loan“). The purchase price was satisfied through the release and discharge of all amounts owing to the Corporation under the Vertical Loan, resulting in the retirement and settlement of the Vertical Loan.

Subsequent Transactions

On July 3, 2020, the Corporation announced the purchase of a US$1.3 million Convertible Promissory Note issued by Galenas (the “$1.3 MM Note“) for a cost of US$1.3 million. The purchase price was satisfied through the issue of an Unsecured Convertible Debenture (“Debenture“) to the sellers of the $1.3 MM Note. The $1.3 MM Note has an interest rate of US$10,400 per month, matures August 1, 2021, and converts, at the Corporation’s option, into 223 membership units of Galenas (approximately 10.3% equity interest).

The Debenture matures on July 3, 2022, has an interest rate of 8.0%, and is convertible at the option of the holder into 26,000,000 Common Shares. The Corporation may, in its sole discretion, extend the maturity date an additional two years, in which case the interest rate shall be 9.2% and the holder may convert the Debenture at its option into 29,900,000 Common Shares. Interest shall accrue and be payable on January 31, April 30, July 31, and October 31 of each year with the initial payment being due July 31, 2020. The Corporation may elect to defer the accrued interest or pay the accrued interest in cash or Common Shares at the prevailing share price (or any combination thereof). The Corporation may force conversion if the Corporation’s 20-day VWAP equals or exceeds US$0.075 per Common Share. Further, if the $1.3 MM Note is retired or sold at less than the outstanding amount under the $1.3 MM Note, the amount owing under the Debenture shall be reduced by the same amount.

COVID-19

The Corporation cautions that current global uncertainty with respect to the spread of the COVID-19 virus and its effect on the broader global economy may have a significant negative effect on the Corporation. While the precise impact of the COVID-19 virus on the Corporation and its US cannabis related investments remain unknown, rapid spread of the COVID-19 virus may have a material adverse effect on global economic activity, and can result in volatility and disruption to global supply chains, operations, mobility of people, consumer spending and the financial markets, which could in turn affect interest rates, credit ratings, credit risk, inflation, business, financial conditions, results of operations for the Corporation’s current and future investments and other factors relevant to the Corporation.

About Vencanna

On September 24, 2018, the Corporation announced the completion of a recapitalization financing, the appointment of a new management team and board of directors and commencement of trading on the CSE. The transactions have transitioned the Corporation from an oil and gas issuer to a merchant capital firm, rebranded as “Vencanna Ventures”. The recapitalized Corporation aims to be a go-to capital provider for early-stage global cannabis initiatives with an emphasis on strong management operating in state compliant jurisdictions with barriers to entry. The Corporation looks to provide investors with a diversified, high-growth, cannabis investment strategy through strategic investments focused through-out the value chain (cultivation, processing and distribution, and including ancillary businesses).

Forward-Looking Statements

This news release may include forward-looking statements including opinions, assumptions, estimates, the Corporation’s assessment of future plans and investment strategy, and, more particularly, statements concerning the business plan of the Corporation including future global cannabis investments and the effects of the COVID-19 pandemic. When used in this MD&A, the words “will,” “anticipate,” “believe,” “estimate,” “expect,” “intent,” “may,” “project,” “should,” and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded on the basis of expectations and assumptions made by the Corporation, including the impact of increasing competition; timing and amount of capital expenditures; the legislative and regulatory environments of the jurisdictions where the Corporation will carry on business, has operations or plans to have operations; the ability of the Corporation to enter into contracts with companies to provide financing on acceptable terms; conditions in general economic and financial markets; and the Corporation’s ability to obtain additional financing on satisfactory terms or at all.  Forward-looking statements are subject to a wide range of risks and uncertainties, and although the Corporation believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized.

Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to, changes to global cannabis laws, how the developing U.S. legal regime will impact the cannabis industry, potential negative impacts from the COVID-19 pandemic, the ability of the Corporation to implement its corporate strategies, the state of domestic and international capital markets, the ability to obtain financing, changes in general market conditions and other factors more fully described from time to time in the reports and filings made by the Corporation with securities regulatory authorities. Except as required by applicable laws, the Corporation does not undertake any obligation to publicly update or revise any forward-looking statements.”

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Source Article